Article

Alcon to acquire LenSx Lasers

Alcon Laboratories announced that it has entered into a definitive agreement to acquire LenSx Lasers Inc., a privately held company located in Aliso Viejo, CA, that developed the first femtosecond laser to receive FDA clearance for use as a part of cataract surgery.

Huenenberg, Switzerland-Alcon Laboratories announced that it has entered into a definitive agreement to acquire LenSx Lasers Inc., a privately held company located in Aliso Viejo, CA, that developed the first femtosecond laser to receive FDA clearance for use as a part of cataract surgery.

The LenSx system is indicated for anterior capsulotomy and laser phacofragmentation during cataract surgery, providing a complementary surgical approach to certain manual steps within the traditional cataract procedure.

Alcon said in a prepared statement that it will pay $361.5 million in cash at closing to LenSx shareholders for their shares, plus maximum contingent payments of $382.5 million based upon the achievement and over-achievement of future femtosecond unit and procedure fee revenue milestones. The closing of this acquisition is subject to receipt of required regulatory approvals and customary closing conditions.

“This complementary technology aligns with Alcon’s strategic focus to help surgeons improve every step of the cataract procedure,” said Stuart Raetzman, vice president, Global Marketing and area president for the United States. “The LenSx laser provides surgeons a new level of predictability and control over critical manual steps during cataract removal - making those steps more precise and reliable.”

Added LenSx President and Chief Executive Officer Ronald Kurtz, MD, “This acquisition further strengthens patient choice in cataract surgery while offering new opportunities for ophthalmic surgeons and surgical centers worldwide.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.